Evidence map›Paper›PMID 26075276›Full record

Trial reportBioMed research international2015

Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.

Hicham El Maaroufi, Agathe Goubard, Rabah Redjoul, Patrick Legrand, Cécile Pautas, Mohamed Mikdame, Kamal Doghmi, Andréa Toma, Sébastien Maury, Michael Schwarzinger and 1 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Proposal of a clinical score to stratify the risk of multidrug-resistant gram-negative rods bacteremia in cancer patients.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Hicham El MaaroufiAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France ; Haematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco.
Agathe GoubardMicrobiology Laboratory, Henri Mondor Hospital, 94000 Créteil, France.
Rabah RedjoulAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France.
Patrick LegrandMicrobiology Laboratory, Henri Mondor Hospital, 94000 Créteil, France.
Cécile PautasAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France.
Mohamed MikdameHaematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco.
Kamal DoghmiHaematology Department, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco.
Andréa TomaAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France.
Sébastien MauryAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France.
Michael SchwarzingerEquipe ATIP/AVENIR, INSERM, UMR 738, 75018 Paris, France ; University Paris Diderot, Sorbonne Paris Cité, UMR 738, 75018 Paris, France.
Catherine CordonnierAssistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France.
Assistance Publique – Hôpitaux de Paris · FRHôpital Militaire Moulay Ismail · MAHôpitaux Universitaires Henri-Mondor · FRUniversité Paris-Est Créteil · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBacterial resistance is of growing concern in haematology wards. As the inappropriate administration of empirical antibacterial may alter survival, we studied risk factors for resistance to our usual empirical first-line antibacterial therapy, cefepime.

methodsWe retrospectively studied 103 first episodes of bacteraemia recorded in our haematology department over 2.5 years. Risk factors for cefepime-resistance were identified by multivariate logistic regression with backward selection (P < 0.05). A scoring system for predicting cefepime-resistance was built on independent factor, with an internal validation by the bootstrap resampling technique.

results38 (37%) episodes were due to Gram-negative bacteria. Fifty (49%) were due to bacteria resistant to cefepime. Cefepime resistance was significantly associated with a decreased survival at day 30 (P < 0.05). Three risk factors were independently associated with cefepime-resistance: acute lymphoblastic leukaemia; ≥18 days since hospital admission; and receipt of any β-lactam in the last month. Patients with ≥2 of these risk factors had a probability of 86% (CI 95%, 25 to 100%) to carry a cefepime-resistant strain.

conclusionUsing our scoring system should reduce the indication of very broad antibacterial regimens in the empirical, first-line treatment of febrile hematology patients in more than 80% of the cases.

Indexed as

BacteremiaGram-Negative BacteriaAdultAgedCefepimeCephalosporinsDrug Resistance, BacterialFemaleHospital DepartmentsHumansMaleMicrobial Sensitivity TestsMiddle AgedCefepimeCephalosporins

Identifiers

PMID26075276
PMCPMC4436445
OpenAlexW1561646214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.